HUNTINGTON MEDICAL RESEARCH INSTITUTES

Empagliflozin Significantly Reduces Stroke Size in Preclinical Studies

- Researchers found that empagliflozin (EMPA), an antidiabetic drug, dramatically reduced the size of cerebral infarctions in preclinical stroke models. - In acute treatment, intravenous EMPA reduced stroke size by 74% and decreased brain swelling, showing potential for immediate intervention. - The study suggests EMPA may protect mitochondrial function and reduce free radical damage, offering a novel approach to stroke treatment. - Further research is planned to assess EMPA's effectiveness post-stroke and its long-term impact on neurological function.